BamSEC and AlphaSense Join Forces
Learn More

Protalix BioTherapeutics Inc.

NYSE American: PLX    
Share price (12/20/24): $1.76    
Market cap (12/20/24): $130 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 18 pages ​ Protalix Biotherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan, as Amended
12/34/56
EX-10.1
from 10-Q 17 pages Protalix Biotherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan, as Amended
12/34/56
EX-10.2
from 10-Q 6 pages ​ Confidential Execution Version ​ Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. ​ via Palermo 26/A, Parma, 43122 Italy
12/34/56
EX-10.1
from 10-Q 34 pages Fill/Finish Agreement
12/34/56
EX-10.2
from 8-K 5 pages ​ Dated August 24, 2021 Between ​ ​ Protalix Ltd. ​ as the Company ​ ​ and ​ ​ Altshuler Shaham Trusts Ltd. ​ as Security Trustee ​ ​ ​ ​ ​ 2021 Security Agreement/Debenture Unlimited in Amount ​
12/34/56
EX-10.1
from 8-K 63 pages Amended and Restated Security Agreement Dated as of August 24, 2021 Among Protalix Biotherapeutics, Inc., as Issuer the Guarantors Party Hereto, Wilmington Savings Fund Society, Fsb, as Collateral Agent the Bank of New York Mellon Trust Company, N.A., as 2021 Notes Trustee and the Bank of New York Mellon Trust Company, N.A., as 2024 Notes Trustee
12/34/56
EX-10.1
from 8-K 23 pages Exchange Agreement by and Among Protalix Biotherapeutics, Inc. and the Parties Signatory Hereto Dated as of August 12, 2021
12/34/56
EX-10.3
from 10-Q 3 pages Binding Term Sheet Between Chiesi Farmaceutici S.P.A. (“Chiesi”) and Protalix Ltd. (“Protalix”) for Amending the U.S. and EX-U.S. Exclusive License and Supply Agreements
12/34/56
EX-10.2
from 10-Q 41 pages Technology Transfer and Supply Agreement
12/34/56
EX-10.1
from 10-Q 10 pages Agreement
12/34/56
EX-10.1
from 10-Q 17 pages Protalix Biotherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan
12/34/56
EX-10.2
from 8-K 10 pages Amended & Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 10 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 13 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 11 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 102 pages Portions of This Exhibit Have Been Omitted Pursuant to a Request for Confidential Treatment Pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). the Omitted Portions, Marked by [***], Have Been Separately Filed With the Securities and Exchange Commission. Exclusive U.S. License and Supply Agreement by and Between Chiesi Farmaceutici S.P.A. and Protalix Ltd. July 23, 2018 [***] Redacted Pursuant to Confidential Treatment Request
12/34/56
EX-10.16
from 10-K 89 pages Portions of This Exhibit Have Been Omitted Pursuant to a Request for Confidential Treatment Pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). the Omitted Portions, Marked by [***], Have Been Separately Filed With the Securities and Exchange Commission. Exclusive License and Supply Agreement by and Between Chiesi Farmaceutici S.P.A. and Protalix Ltd. October 17, 2017
12/34/56
EX-10.2
from 8-K 15 pages Exchange Agreement by and Among Protalix Biotherapeutics, Inc. and the Parties Signatory Hereto Dated as of July 24, 2017
12/34/56
EX-10.1
from 8-K 25 pages Note Purchase Agreement
12/34/56